LogicBio Therapeutics Inc
NASDAQ:LOGC
LogicBio Therapeutics Inc
Total Equity
LogicBio Therapeutics Inc
Total Equity Peer Comparison
Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
LogicBio Therapeutics Inc
NASDAQ:LOGC
|
Total Equity
$30.7m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
94%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
$8B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$17.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$5B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-14%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$18.5B
|
CAGR 3-Years
27%
|
CAGR 5-Years
31%
|
CAGR 10-Years
31%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$27B
|
CAGR 3-Years
31%
|
CAGR 5-Years
23%
|
CAGR 10-Years
28%
|
See Also
What is LogicBio Therapeutics Inc's Total Equity?
Total Equity
30.7m
USD
Based on the financial report for Dec 31, 2021, LogicBio Therapeutics Inc's Total Equity amounts to 30.7m USD.
What is LogicBio Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 5Y
94%
Over the last year, the Total Equity growth was -50%. The average annual Total Equity growth rates for LogicBio Therapeutics Inc have been -27% over the past three years , 94% over the past five years .